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Abstract
Background: Previous studies suggested that the abnormality of metabolism is a newly identified risk factor in
HBV-related hepatocellular carcinoma (HCC). The association between metabolic factors and hepatocellular
carcinoma (HCC) has not been clarified up to now. This study was conducted to investigate the prevalence of
metabolic abnormalities in HCC and to probe the association between metabolic parameters and liver function as
well, so as to evaluate the interactions between metabolism and the development of HBV-related HCC.
Methods: Totally 179 cases of HBV-related HCC, who were surgically treated and pathologically confirmed were
enrolled. HBV carriers (n = 100) and healthy controls (n = 150) were recruited from routine physical examination during
the same period. Body mass index (BMI) was obtained from medical documentation. All the metabolic-related
parameters and liver function tests were determined with routine biochemical or immunological analytic methods.
Malondialdehyde (MDA) and total antioxidant capacity(TAOC)were detected by chemical analytic methods. A stratified
analysis was conducted according to BMI, glycated albumin (GA), free fatty acids (FFA), and the relationships between
the metabolic-related parameters and liver functions were analyzed in HCC and control subjects.
Results: HCC group showed significantly high levels of mean BMI, serum glucose, low serum lipids levels than
controls (P < 0.05). Acquired by stratified analysis, the higher the BMI, the higher level of insulin and homeostasis
model assessment for insulin resistance (HOMA-IR) (P < 0.01) were found in HCC patients. Elevated level of MDA
and g-glutamyltransferase (GGT) were revealed in those with high serum FFA level for the first time. Strong
associations between metabolic factors and liver function were shown in HCC (P < 0.05). Higher GA level was
strongly associated with increased risk of cancer compared to healthy controls (OR = 9.87, 95% confidence interval:
1.86~52.29). Serum triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C) levels were negative
contributory factors for HCC (OR = 0.05, 95% confidence interval: 0.01~0.27 and OR = 0.32, 95% confidence interval,
0.11~0.95: respectively).
Conclusions: Metabolic abnormalities are closely associated with the occurrence and development of HBV-related
HCC. Oxidative stress and/or lipid peroxidation might be involved in the pathogenesis and acceleration of liver
function impairments in HCC.
Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer and the third cause of cancer-related death
worldwide [1]. It has been a major concern in both
Western and Asia countries. As known to all, the high
prevalence of hepatitis B and C gives rise to the high
incidence of HCC. At the same time, so many con-
founding factors are associated with the occurrence and
development of chronic liver diseases [2]. Recently, the
relationship between metabolic factors and chronic liver
diseases including liver cirrhosis (LC) and hepatocellular
carcinoma (HCC) has become a hot topic [3].
Metabolic syndrome (MS) has been recognized as a
major public health problemw o r l d w i d ea r o u s i n gm o r e
attentions. MS is a collection of metabolic abnormalities,
including abdominal obesity, blood lipid barrier,
* Correspondence: gaocf1115@163.com
1Department of Laboratory Medicine, Eastern Hepatobiliary Surgery Hospital,
Second Military Medical University, Shanghai, China
Full list of author information is available at the end of the article
Zhao et al. Nutrition Journal 2011, 10:49
http://www.nutritionj.com/content/10/1/49
© 2011 Zhao et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.diabetes, hypertension. MS is interrelated with insulin
resistance, which is also known as insulin resistance syn-
drome [4]. Nonalcoholic fatty liver disease (NAFLD) as
the hepatic manifestation of MS, has been revealed to
be associated with insulin resistance [5]. NAFLD is no
longer a disease happened in developed Western coun-
tries. Fan, et al reported that the prevalence of NAFLD
is up to 15% in some urban of China [6]. It was
described as a young disease and could progress to end-
stage liver diseases, from simple fatty liver, steatohepati-
tis to liver cirrhosis and HCC [7,8].
Laboratory tests are useful in reflecting the metabolic
abnormalities or liver function impairments. Abnormal
levels of aminotransferase (ALT) and bilirubin usually
indicate liver functions impairment, but the metabolism
of lipid or blood glucose is also among the important
functions of the liver. Recently some researches reported
that g-glutamyltransferase (GGT) and ALT could predict
the development of MS [9,10]. Although the associations
between metabolic factors and hepatocellular carcinoma
(HCC) have been gradually recognized, fewer investiga-
tions have been made between the metabolic indicators
and HBV-related HCC. Making use of the high preva-
lence of HBV-related HCC in China [11], we designed a
cross-sectional study to clarify the association between
metabolic abnormalities and the development of HBV-
related HCC.
Methods
Subjects and measurements
The study consisted of 179 cases of patients with HBV-
related HCC who were diagnosed and confirmed by
pathology in the Shanghai Eastern Hepatobiliary Surgery
hospital (EHBH) from January to August 2008. Liver cir-
rhosis was revealed in 66.5% (119/179) of HCC patients.
Serum HBsAg was positive in all enrolled HCC. The
HBeAg positive cases accounted for 66.5% (119/179).
The level of serum HBV DNA higher than 10
3 copy/ml
accounted for 63.7% (114/179). The HCC stage was
classified according to the TNM criteria (2002) [12]: T1,
a solitary tumor without vascular invasion; T2, a solitary
tumor with vascular invasion or multiple tumors of 5
cm or less; T3, multiple tumors greater than 5 cm
invading the major branches of portal or hepatic veins;
and T4, tumors with direct invasion of adjacent organs
other than the gallbladder or with perforation of visceral
peritoneum. N0/1, with/without regional lymph node
metastasis. M0/1, with/without distant metastasis. Stage
I, T1N0M0; Stage II, T2N0M0; Stage IIIA, T3N0M0;
Stage IIIB, T4N0M0; Stage IIIC, Tany N1M0; Stage IV,
Tany Nany M1. All the patients’ information was
obtained by hospital medical records. One hundred
cases of HBV carriers were collected from the Shanghai
Changzheng hospital. The HBV carriers was defined as
positive serum hepatitis B surface antigen (HBsAg) for
at least 6 months but who have repeatedly normal (or
minimally raised) liver enzymes and negative tests for
HBeAg before enrolling [13]. Patients with hepatitis A
virus, HCV, hepatitis D virus, hepatitis E virus, human
immunodeficiency virus, Epstein-Barr virus, and cytome-
galovirus infection, alcohol consumption > 30 g/day,
metastatic liver cancer, autoimmune liver disease, drug-
related liver disease, alcoholic hepatitis, obstructive jaun-
dice, other causes of chronic liver disease, renal inade-
quacy or blood diseases were excluded from the patients
cohort. The 150 cases of healthy control were recruited
from routine physical examination in EHBH.
The study protocol was approved by the Chinese
Ethics Committee of Human Resources, Eastern Hepa-
tobiliary Hospital. Informed consents were obtained
both from the patients and the healthy donors.
The information of weight, height, blood pressures,
tumor size and whether there were any violations of
metastasis, medical history, life style characteristics and
other related information were collected from medical
documentation. Body mass index (BMI) was calculated
by dividing body weight in kilograms by the square of
height in meters. Waist circumference was not mea-
sured in this study. According to the standard of obesity
in Chinese population [14], obesity was divided into two
groups, normal BMI level (BMI 18.5 to 23.9 kg/m
2)a n d
abnormal BMI (BMI≥ 24 kg/m
2). Blood specimens were
drawn after 12 h of fasting and were subsequently mea-
s u r e da tt h eD e p a r t m e n to fL a b o r a t o r yM e d i c i n ei n
EHBH. All the blood samples were collected before sur-
gery. The measured liver function indicators were: total
bilirubin (TBIL), direct bilirubin (DBIL), total bile acid
(TBA), total protein (TP), albumin (ALB), prealbumin
(PALB), ALT, aspartate aminotransferase (AST), GGT,
alkaline phosphatase (ALP). Indicators of lipid metabo-
lism consisted of FFA, TG, total cholesterol (TC), LDL-
cholesterol (LDL-C), apolipoprotein B (ApoB). Relevant
indicators of glucose metabolism included glycated albu-
min (GA), fasting glucose, insulin and C-peptide. All the
measurements were performed on HITACHI 7600 auto-
matic biochemical analyzer with matched reagents.
High-density lipoprotein cholesterol (HDL-cholesterol,
HDL-C) was calculated by the Friedewald equation [15].
Quantitative insulin sensitivity check index (QUICKI)
[16] and homeostasis model assessment for insulin resis-
tance (HOMA-IR) were calculated to evaluated insulin
resistance [17]. Oxidative stress marker MDA was mea-
sured using the thiobarbituric acid-reactive substances
(TBARS) assay, TAOC was measured with Fe
3+ reduc-
tion method. Alpha-fetoprotein (AFP), carcino-embryo-
nic antigen (CEA) and CA19-9 were determined on
Roche E170 with chemiluminescence; Hepatitis B virus
related surface antigen and antibody were detected by
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particle immunoassay (CMIA).
Statistical analysis
The statistical analyses were conducted using SPSS ver-
sion 11.5 statistical software Data were presented as
median and range for nonparametric variables and
mean ± SD for parametric variables. One-way analysis
of variance for non-parametric data was performed by a
post hoc analysis using Kruskal-Wallis H test. Para-
metric variables were compared by post hoc analysis
using Tukey test. BMI, GA, FFA were classified into
categories so as to make stratified analysis. Categorical
variables were compared using a Mann-Whitney U test.
For analysis of the correlation between two indicators
(liver functions and metabolic parameters), spearman
correlation analysis was performed. For multivariate
analysis, multivariate logistic regression analysis was
applied. The OR was used to estimate the relative risk
of HCC. All p-values were two-tailed and p-values less
than 0.05 were considered significant.
Results
The general demographic information of all the subjects
was listed in Table 1. There were significant differences
in TBIL, TP, ALB, ALT, AFP among HCC patients,
HBV carrier and healthy controls (p < 0.05). Stages of
HCC were 49 (27.37%) in I, 69 (38.55%) in II, 49
(27.37%) in III and 6 (3.35%) in IV by TNM classifica-
tion. The metabolic parameters of the three groups were
displayed in Figure 1. HCC group showed significantly
lower levels of TC, TG and higher levels of GA than
both diseased and healthy controls (p < 0.01), while sig-
nificantly higher levels of MDA and lower levels of
TAOC were revealed in HCC (p < 0.01). Though there
was no difference for LDL-C between HCC ptients and
HBV carriers, LDL-C was higher in HCC patients than
that in healthy controls (p < 0.01).
The impacts of BMI, GA, FFA on liver functions as well
as on the other metabolic parameters were revealed in
Table 2. With the increasing of BMI, the higher level of
GLU, HOMA-IR, Insulin, QUICKI, FFA, TG and LDL-C.
(p < 0.05) were found in HCC patients. There was no sig-
nificant difference of liver function in different BMI sub-
groups. GLU and ALP were significant higher in higher
GA group than that in normal GA after stratified by GA
at the borderline value (p < 0.05). Similarly, FFA was used
to classify the subjects into abnormal (higher) and normal
group, MDA and GGT were significantly higher in abnor-
mal group than that in normal one (p < 0.05). We failed to
find any differences between the TNM stages and the
metabolic parameters or liver functions (data not shown).
The association study revealed that the parameters
reflecting liver function were correlated with metabolic
indicators (Table 3). Especially the liver enzymes, AST
and ALP, were positively correlated with QUICKI, GA,
INS, (p < 0.05) and negatively correlated with IR. GGT
was correlated with FFA and HDL-C (p < 0.05). The
association study among metabolic parameters in HCC
patients showed that BMI was positively associated with
IR, INS, C-peptide and negatively related with QUICKI
and GA. MDA was positively associated with FFA and
negatively related with HDL. TAOC was correlated with
TC, TG and HDL-C (p < 0.05) (Table 4).
GA, TG, LDL and HDL were shown as risk factors for
HCC after stepwise multiple regression analysis (Table
5). High GA level was strongly associated with increased
risk of cancer compared to healthy control (OR, 9.87;
95% CI, 1.86~52.29) and HBV carriers (OR, 16.67; 95%
CI, 1.89~147.3). Interestingly serum TG levels were
strongly associated with reduced risk of cancer develop-
ment (OR = 0.05, 95% CI: 0.01~0.27) and HBV carriers
(OR = 0.12, 95% CI: 0.04~0.37) respectively. The risk of
cancer was also markedly attenuated with higher LDL-C
levels (OR = 0.32, 95% CI: 0.11~0.95). Low HDL-C was
strongly associated with increased risk of HBV carriers
(OR = 11.81, 95% CI: 2.37~58.91) and HCC develop-
ment (OR = 11.99, 95% CI: 1.8~77.56) respectively.
The above results were also achieved after stratified
analysis by age (see Additional file 1 Table S1-S3) and
Table 1 Characteristics of all enrolled subjects
Indices Healthy (X ± SD) HBV(X ± SD) HCC(X ± SD) F p
AGE 47.48 ± 8.05 46.85 ± 12.06 52.45 ± 9.85 15.89 0.00
Sex Male(118) Male(66) Male(155) 16.43 0.00
Female(32) Female(34) Female(24)
TBIL(μmol/L) 12.64 ± 5.08 15.54 ± 8.67 16.38 ± 14.16 4.709 0.009
TP(g/L) 77.71 ± 3.25 78.49 ± 4.90 71.23 ± 6.04 98.155 0.00
ALB(g/L) 47.20 ± 2.24 48.27 ± 2.21 40.91 ± 3.96 250.025 0.00
ALT (U/L) 22.46 ± 15.00 31.33 ± 20.37 54.13 ± 65.15 20.005 0.00
AFP(μg/L) 2.8(1.82-3.88) 1.54(1.13-2.28) 34.4(5-1210) 149.83 0.00
Data were presented as mean ± SD, or median and range. Differences in continuous variables were evaluated by One-way analysis of variance with post hoc
analysis using Tukey test and Kruskal-Wallis test.
* p value < 0.05 was considered statistically significant.
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HBV carriers and 150 cases of healthy controls were recruited. The liver function indicators and GA were measured on HITACHI 7600 automatic
biochemical analyzer with matched reagents. Oxidative stress marker malondialdehyde (MDA) was measured using the thiobarbituric acid-
reactive substances (TBARS) assay, total antioxidant capacity (TAOC) was measured with Fe
3+ reduction method. HCC group showed significantly
lower levels of TC, TG and higher levels of GA than both diseased and healthy controls (p < 0.01), while significantly higher levels of MDA and
lower levels of TAOC were revealed in HCC (p < 0.01). LDL-C was higher in HCC than that in healthy controls (p < 0.01). Data were expressed as
percentages ± standard error. * p value < 0.01 vs. control. Parametric variables were compared by post hoc analysis using Tukey test.
Table 2 Changes of metabolic parameters and liver functions in HCC subjects with different BMI, GA, FFA
BMI(median) P GA(median) P FFA(median)or (X±SD) P
<24 kg/cm
2 ≥24 kg/cm
2 ≤16% >16% ≤0.6 >0.6
BMI (kg/m2) 22.6
(20.70~25.19)
23.24
(21.15~24.67)
0.86 22.45
(21.68~24.73)
24.67
(20.62~26.08)
0.45
GA 15(14~16) 16(13~16) 0.08 15.5(14~16) 14.5(14~16) 0.18
GLU (mmol/L) 4.96(4.48~5,23) 5.2(4.68~5.39) 0.03 4.86 (4.54~5.1) 6.43(5.06~6.59) 0.00 5.03(4.59~5.38) 5.17(4.67~5.39) 0.64
INS (μU/L) 7.46(3.79~7.47) 7.77(5.15~10.18) 0.00 7.46(3.97~8.93) 9.06(3.92~10.03) 0.81 7.32 (4.15~9.16) 8.32(4.29~10.38) 0.29
C-peptide (nmol/
L)
1.18(0.84~1.39) 1.18(1.13~1.95) 0.00 1.16(0.91~1.55) 1.26(0.96~1.53) 0.92 1.18(1.0~1.56) 1.24 (1.16~2.0) 0.04
IR 1.53(0.8~1.62) 1.9(1.11.~2.54) 0.00 1.43(0.87~2.03) 3.16(0.90~2.44) 0.07 1.5(0.90~2.06) 2.59 (1.12~2.41) 0.11
QUICKI 0.36(0.35~0.39) 0.35(0.33~0.37) 0.00 0.36(0.34~0.39) 0.32(0.33~0.39) 0.07 0.36(0.34~0.38) 0.33(0.33~0.37) 0.11
FFA (mmol/L) 0.39(0~0.54) 0.61(0~0.58) 0.03 0.46(0~0.56) 0.5(0.1~0.57) 0.32
TC(mmol/L) 3.60(3.31~4.42) 4.44(3.55~4.71) 0.04 3.84(0.35~0.46) 4.26(3.42~4.49) 0.59 3.83(3.4~4.48) 4.32(3.63~4.67) 0.36
TG(mmol/L) 0.79(0.61~1.02) 1.20(0.83~1.31) 0.00 1.17(0.68~1.17) 0.79(0.64~1.05) 0.38 1.05(0.73~1.17) 1.12(0.8~1.21) 0.63
LDL(mmol/L) 2.24(1.92~2.64) 2.77(2.2~3.04) 0.00 2.42(1.93~2.86) 2.61(1.95~2.77) 0.68 2.39(1.96~2.87) 2.4(2.02~2.89) 0.70
HDL(mmol/L) 1.31(1.14~1.59) 1.38(1.09~1.48) 0.04 1.32(1.08~1.48) 1.35(1.22~1.63) 0.03 1.33(1.07~1.49) 1.35(1.19~1.53) 0.46
MDA(nmol/mL) 10.75(7.48~15.8) 10.88
(6.22~14.05)
0.34 10.63
(6.97~15.38)
12(6.38~14.73) 0.98 11.24 ± 6.74 15.03 ± 12.33 0.03
TAOC(U/ml) 12.03
(10.64~17.13)
15.36
(10.36~18.19)
0.21 12.46
(10.47~17.04)
16.84
(11.63~18.53)
0.05 11.96(9.22~17.51) 14.4(10.85~17.82) 0.20
ALB(g/L) 41.6
(38.45~43.63)
39.6(38.6~43.2) 0.84 41.6(39.04~43.7) 39.2(37.2~42) 0.02 41.8(38.74~43.49) 39.95
(37.13~42.08)
0.10
ALT(U/L) 30.2
(26.53~55.93)
44.5(26.5~53.4) 0.89 30.2
(25.95~53.75)
49.9(32.15~56.7) 0.27 38.85
(25.65~56.65)
31.95
(29.18~56.35)
0.72
AST(U/L) 34.6
(29.68~55.68)
34.9(25.4~58.2) 0.10 33.5
(26.43~53.53)
44.6(29.65~64.25) 0.12 34.85(27.2~51.5) 31.62
(30.03~66.75)
0.14
ALP(U/L) 97(76~122) 79(63~105) 0.06 84(67~110.25) 112(82~144) 0.01 88.5(70.5~113) 89(74.5~159.25) 0.07
GGT(U/L) 77(40~171) 55(36~123) 0.30 65(36~135) 77(42~109) 0.60 62(35.5~99) 144(81~215.5) 0.00
Data were presented as median and range. Differences were regarded as significant at 0.05 in a Mann-Whitney U test.
*p value < 0.05 was considered statistically significant.
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size was negatively associated with TG (p < 0.05) and
positively related to GGT (p < 0.01) (see Additional
file 3 Figure S1).
Discussion
Metabolic syndrome is composed of a complex constel-
lation of factors, that namely glucose intolerance and
insulin resistance, central obesity, dyslipidemia,
hypertension [4,18,19]. Over the past decade several
researches have produced preliminary clues on the rela-
tionship between metabolic syndrome and hepatocellu-
lar carcinoma [20,21]. However, few studies have
investigated the association between metabolic factors
and HBV-related HCC. As with the development of
economy and changing of living behavior, metabolic-
related chronic diseases have become more common in
China. The present study extended the research on
metabolic abnormalities in HBV related HCC in Chinese
populations.
Insulin resistance and obesity, the majority compo-
nents of MS are often revealed to be linked with cancer
and now widely recognized as significant risk factors for
HCC [22-24]. Our data displayed that with the increas-
ing of BMI, the higher level of GLU, HOMA-IR, Insulin,
QUICKI, FFA, TG and LDL-C. (p < 0.05) were found in
HCC. Similar study demonstrated that HOMA-IR, a
marker of insulin resistance, is elevated with increasing
BMI[25]. The link between obesity/diabetes and HCC
may be explained by oxidative stress and/or lipid peroxi-
dation that increase the possibility of hepatic injury,
fibrosis, and even cirrhosis result from hepatic inflam-
mation [26,27]. Increased plasma insulin concentration
combined with impaired whole-body glucose clearance
in the present study was most likely a consequence of
decreased insulin sensitivity, a typical phenomenon in
patients with malignant diseases [28,29].
In investigation the existence of oxidative stress and/
or lipid peroxidation in HCC, we measured MDA and
TAOC in all subjects. MDA is the lipid peroxidation
end product and an important player in oxidative stress.
Table 3 Association study among liver functions, tumor markers and metabolic parameters in HCC
BMI IR QU GA GLU INS C-peptide FFA TC TG LDL HDL
TBIL r -0.034 0.02 -0.02 0.092 0.018 0.019 0.043 0.188 0.091 -0.228 0.032 0.236
p 0.663 0.8 0.8 0.222 0.816 0.806 0.573 0.036 0.23 0.002 0.0675 0.002
ALB r 0.018 0.186 -0.186 -0.248 -0.019 0.196 0.08 -0.08 0.165 -0.016 0.189 -0.009
p 0.813 0.015 0.015 0.001 0.8 0.01 0.296 0.377 0.029 0.838 0.012 0.902
ALT r -0.03 -0.013 0.013 0.08 0.102 -0.057 0.056 0.103 -0.024 0.064 -0.057 0.018
p 0.694 0.863 0.863 0.289 0.175 0.459 0.467 0.252 0.753 0.403 0.449 0.814
AST r -0.183 -0.217 0.217 0.188 -0.02 -0.241 -0.079 0.161 0.051 -0.073 -0.007 0.141
p 0.017 0.004 0.004 0.013 0.79 0.002 0.305 0.073 0.502 0.339 0.931 0.062
ALP r -0.204 -0.25 0.25 0.272 0.043 -0.302 -0.156 0.125 -0.054 -0.012 -0.125 0.111
p 0.008 0.001 0.001 0 0.571 0 0.042 0.166 0.476 0.879 0.098 0.143
GGT r -0.099 -0.102 0.102 0.063 -0.036 -0.136 0.033 0.311 0.1 0.063 0.035 0.174
p 0.248 0.232 0.232 0.452 0.665 0.11 0.699 0.002 0.235 0.459 0.675 0.037
PT r -0.063 -0.175 0.175 0.231 -0.089 -0.158 -0.15 0.107 -0.29 -0.242 -0.317 -0.084
p 0.412 0.022 0.022 0.002 0.237 0.037 0.049 0.236 0 0.001 0 0.266
AFP r -0.071 -0.091 0.091 -0.054 -0.131 -0.065 -0.108 0.069 -0.007 -0.115 -0.005 0.002
p 0.35 0.232 0.232 0.475 0.08 0.393 0.159 0.443 0.924 0.13 0.949 0.974
The correlation between two indicators (liver functions and metabolic parameters), spearman correlation analysis was performed.
* p value < 0.05 was considered statistically significant.
Table 4 Association study between metabolic parameters
in HCC
BMI FFA TC TG LDL HDL
IR r 0.391 0.208 0.122 0.179 0.14 -0.095
p 0.000 0.023 0.109 0.019 0.067 0.214
QUICKI r -0.391 -0.208 0.122 -0.179 -0.14 0.095
p 0.000 0.023 0.109 0.019 0.067 0.214
GA r -0.21 0.133 0.005 -0.218 0.121 0.311
p 0.006 0.138 0.947 0.004 0.107 0.000
GLU r 0.117 0.081 0.032 0.127 0.044 -0.033
p 0.127 0.368 0.67 0.094 0.563 0.665
INS r 0.416 0.146 0.133 0.148 0.155 -0.082
p 0.000 0.112 0.08 0.054 0.042 0.282
C peptide r 0.376 0.194 0.128 0.205 0.152 -0.104
p 0.000 0.034 0.094 0.007 0.046 0.171
MDA r -0.062 0.213 -0.13 -0.035 0.081 -0.168
p 0.421 0.019 0.086 0.648 0.287 0.026
TAOC r 0.113 0.083 0.172 0.224 0.112 0.155
p 0.151 0.377 0.025 0.003 0.146 0.043
The correlation between two indicators (metabolic parameters), spearman
correlation analysis was performed.
* p value < 0.05 was considered statistically significant.
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indices of oxidative stress to evaluate the oxidative
damage in diseased status[30]. TAOC is an index of the
antioxidative defense system. We found for the first
time that elevated levels of oxidative stress(MDA) and
decreased antioxidative capacity (TAOC) were revealed
in HCC patients. The results were consistent with the
finding that HBV infection could increase toxic oxida-
tion products, which lead to oxidative stress and DNA
damage [31,32]. HBV X protein has drawn considerable
attention to the generation of HCC via mitochondria-
derived reactive oxygen species (ROS). ROS could acti-
vate kupffer cells modulating hepatocyte injury and gen-
erating ROS, accompanied by lipid peroxidation, further
impairment of mitochondrial function, which contribu-
ted much to carcinogenesis [32]. In addition, ROS are
most potent and can modify DNA methylation [33,34].
But what predominates the extent of liver injury in
HBV-related HCC and how abnormal metabolism accel-
erates the pathogenesis of HCC remain to be elucidated.
The liver is a critical organ in maintaining glucose and
lipid homeostasis. The decreased glucose metabolism,
utilization and downregulation of triglyceride synthesis
in HCC patients were revealed in this study. ALT as an
indicator of liver injury was obviously elevated in HCC
in our observation (table 1). The elevation of ALT levels
might be the reflection of excess accumulation of fat in
the liver because of various metabolic abnormalities and
indicated ongoing inflammation which impairs insulin
signaling in the liver [35-37]. Our further logistic regres-
sion analysis revealed that lower TG and cholesterol
levels as well as higher GA were contributing factors to
HCC (Table 5). Meanwhile we found that the inverse
correlation between serum TG and tumor size, the posi-
tive correlation between tumor size and GGT (supple-
mentary Figure 1). These interesting observations
indicate the intimate relation between lipid or glucose
metabolisms and HBV-related malignancies, The contra-
dicatory associations, ie. the inverse and positive correla-
tions between lipid metabolisms and HCC, as revealed
by us and others further demonstrated the complicated
process of dyslipidemia involved in the pathogenesis
HCC[26,38,39]. Though the mechanism how HBV-
related diseases were closely related to lipid metabolisms
is not clarified up to now, there are several studies sup-
porting our findings: (1) HBV infection disturbs liver
lipid metabolism, which was reported by Jan et al and
revealed that low serum TG level was also associated
with chronic HBV infection [40]. Another independent
in vitro study had ever demonstrated that HBX protein
could directly inhibit secretion of ApoB, an essential
component of LDL-C and very-low-density lipoprotein
(VLDL-C), via promoting high expression of N-acetyl-
glucosaminyltransferase III, in cell culture [41,42]. (2)
Lipids and lipoprotein metabolisms could be regulated
by cytokines, while tumor cells are known to produce
large amounts of pro-inflammatory cytokines. For
instance, interleukin-6 (IL-6), tumor necrosis factor (TNF-
a), IL-1 may inhibit TG synthesis [43]. (3)The change of
general nutritional status in exhaustive malignant diseases
is another important factor leading to dyslipidemia. Low
levels of TG and cholesterol were also revealed in other
malignancies including colorectal cancer, lung cancer and
so on [44-47]. Although our findings of inverse relation-
ship between TG level and HCC were also consistent with
previous study[26,48], the possibility that low TG was a
consequence of malignant liver diseases (HCC) can not be
excluded. Hence further prospective study should be
designed to elucidate the causative or consequent effect or
even both causative and consequent effects of dyslipidemia
in HBV-related HCC in future study.
Another important metabolic indicator which could be
linked with obesity is FFA. FFA is normally released
from an expanded adipose tissue and produced an
increased secretion of VLDL. MDA, the lipid peroxida-
tion end product via fatty acid b-oxidation, was found
to be associated with FFA in this study. Our result
further confirmed that obesity might be related with
liver injury and eventual accelerating the development
of HCC [49,50].
Table 5 Multiple logistic regression analysis to explore risk factors contributing to HCC
HCC vs controls
OR(95%CI)
P values HCC vs HBV carrier
OR(95%CI)
P values HBV carrier vs controls
OR(95%CI)
P values
GA
≧16 9.87 (1.86~52.29) 0.007 16.67(1.89~147.3) 0.011 0.60 (0.05~7.15) 0.680
TG(mmol/L)
≧2.29 0.05 (0.01~0.27) 0.001 0.40 (0.07~2.20) 0.293 0.12 (0.04~0.37) 0.000
LDL(mmol/L)
≧3.11 0.32 (0.11~0.95) 0.040 0.80(0.25~2.57) 0.705 0.4 (0.17~0.96) 0.040
HDL(mmol/L)
<0.92 11.99 (1.8~77.56) 0.090 1.02 (0.25~4.10) 0.983 11.81 (2.37~58.91) 0.003
Multivariate logistic regression analysis was applied.
* p value < 0.05 was considered statistically significant.
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Page 6 of 8There are some limitations of this study. HBV carrier
was used as disease control instead of CLD (fibrosis and
cirrhosis). Metabolic abnormality might develop in CLD
and abnormal metabolism could accelerate the progress
of CLD at the same time. Further validation in CLD
groups and in large sample size were required to illus-
trate the value of metabolic assessment in the prediction
and prognosis in HCC. Another limitation is that the
research is a cross-sectional study drawn from a clinical
series of patients and not from the community. But the
cases were carefully matched or stratified by age, gender,
BMI, time of hospital admission and etiology to mini-
mize the interferences. A better understanding of the
relationship between these metabolic parameters should
ultimately lead to improve prediction and treatment
options for patients with HBV related HCC. To counter-
act the adverse effects of metabolic abnormalities, those
infected with HBV should first attempt to achieve the
metabolic control through changes in diet and life style.
Conclusions
This study concluded that metabolic abnormalities are
closely associated with the occurrence and development
of HBV-related HCC. Oxidative stress and/or lipid per-
oxidation identified in HCC might be involved in the
pathogenesis. The predictive value of metabolism para-
meter and the pathogenesis of abnormal metabolism in
HCC require further validation in future study.
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